Cardiovascular

Hasten and LIB Therapeutics enter $325m CVD drug development deal

‍Hasten Biopharmaceutical has signed an agreement to acquire the rights for the development and commercialisation of LIB Therapeutics’ cardiovascular disease (CVD) drug…

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Novo Nordisk has entered a research collaboration with the Broad Institute of Massachusetts Institute of Technology and Harvard to detect…

New 2023 guidelines for the management of cardiomyopathies

A new set of European Society of Cardiology (ESC) guidelines was shared at the 2023 ESC conference in Amsterdam, Netherlands.…

AstraZeneca receives China’s NMPA approval for Forxiga

AstraZeneca has received approval from China’s National Medical Products Administration (NMPA) for Forxiga (dapagliflozin) to reduce the risk of cardiovascular mortality,…

Innovent receives approval from China’s NMPA for SINTBILO

Innovent Biologics has secured approval from China's National Medical Products Administration (NMPA) for SINTBILO (tafolecimab injection, anti-PCSK9 monoclonal antibody) to…

Ionis and Novartis to develop medicine for cardiovascular disease

Ionis Pharmaceuticals has signed a collaboration and licence agreement with Novartis to advance a next-generation programme targeting lipoprotein(a) (Lp(a)) for…

Boehringer and Lilly secure EC approval for Jardiance to treat adults with CKD

Boehringer Ingelheim and Eli Lilly have secured approval from the European Commission (EC) for Jardiance (empagliflozin) to treat adults with…

Lilly to acquire biopharma firm Versanis for $1.9bn

Eli Lilly and Company has signed an agreement for the acquisition of clinical-stage biopharmaceutical firm Versanis Bio in a $1.925bn deal. Versanis…

EC approves BMS’ Camzyos for hypertrophic cardiomyopathy

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten, 2.5mg, 5mg, 10mg, 15mg capsules) to treat adults…

CMP Pharma offers oral suspension for cholesterol reduction

CMP Pharma has announced the availability of Atorvaliq (atorvastatin calcium), a liquid suspension of Atorvastatin, to treat high cholesterol and…